Physician profile
June Kim
NPI 1144491929
$1,196.34
in general payments reported to CMS, 2019-2025
15 companies · $351 in 2025
The $351 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $26.66 · 2021: $131 · 2023: $318 · 2024: $104 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.44 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $237.04 | 2023-2025 | Breztri, Saphnelo |
| Glaxosmithkline, LLC. | $138.49 | 2025 | Nucala |
| Insmed, INC. | $138.16 | 2023-2025 | Arikayce |
| Jazz Pharmaceuticals INC. | $122.91 | 2019 | |
| United Therapeutics Corporation | $112.24 | 2021 | |
| Depuy Synthes Sales INC. | $107.40 | 2023 | Spine & Trauma 3d Navigation, Vivigen Mis Delivery System, Viper |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.04 | 2019-2025 | Ofev, Jascayd |
| Breathe Technologies, INC. | $70.42 | 2019 | |
| Vapotherm INC | $49.44 | 2023 | Vapotherm |
| Astellas Pharma US INC | $38.07 | 2019 | |
| Dynavax Technologies Corporation | $26.66 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.10 | 2025 | |
| Alcresta Therapeutics, INC. | $22.50 | 2019 | |
| Optinose US, INC. | $18.15 | 2024 | |
| Philips North America LLC | $14.72 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw June Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.